HC Wainwright Reiterates Buy Rating for Gain Therapeutics (NASDAQ:GANX)

Gain Therapeutics (NASDAQ:GANX)‘s stock had its “buy” rating reaffirmed by research analysts at HC Wainwright in a note issued to investors on Monday,Benzinga reports. They currently have a $8.00 target price on the stock. HC Wainwright’s target price suggests a potential upside of 279.15% from the stock’s previous close.

A number of other research firms have also issued reports on GANX. Roth Mkm restated a “buy” rating and set a $7.00 price objective on shares of Gain Therapeutics in a research report on Tuesday, December 24th. Roth Capital upgraded Gain Therapeutics to a “strong-buy” rating in a research note on Thursday, December 5th. Finally, Scotiabank began coverage on shares of Gain Therapeutics in a research report on Friday, March 7th. They set a “sector outperform” rating and a $12.00 price target for the company. Five investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Buy” and a consensus target price of $8.20.

Gain Therapeutics Stock Performance

Shares of GANX stock opened at $2.11 on Monday. The company has a market cap of $55.97 million, a P/E ratio of -1.92 and a beta of 0.14. The business has a 50 day moving average of $2.23 and a two-hundred day moving average of $1.99. Gain Therapeutics has a 52 week low of $0.89 and a 52 week high of $4.63. The company has a quick ratio of 2.99, a current ratio of 2.99 and a debt-to-equity ratio of 0.04.

Institutional Trading of Gain Therapeutics

Several hedge funds have recently added to or reduced their stakes in the business. Geode Capital Management LLC grew its stake in shares of Gain Therapeutics by 48.0% in the third quarter. Geode Capital Management LLC now owns 271,972 shares of the company’s stock worth $484,000 after purchasing an additional 88,236 shares in the last quarter. Jones Financial Companies Lllp lifted its holdings in Gain Therapeutics by 83.6% in the fourth quarter. Jones Financial Companies Lllp now owns 98,250 shares of the company’s stock worth $212,000 after purchasing an additional 44,750 shares during the period. Marshall Wace LLP bought a new position in Gain Therapeutics in the 4th quarter valued at about $198,000. Northern Trust Corp increased its stake in Gain Therapeutics by 88.2% during the 4th quarter. Northern Trust Corp now owns 84,586 shares of the company’s stock valued at $183,000 after buying an additional 39,642 shares during the period. Finally, Bridgeway Capital Management LLC acquired a new position in Gain Therapeutics during the 4th quarter valued at about $65,000. Institutional investors own 11.97% of the company’s stock.

About Gain Therapeutics

Gain Therapeutics, Inc, a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease.